November 17, 2021
On behalf of the UCLA AIDS Treatment and Prevention CTU, the CARE CRS Outreach Team would like to cordially invite you to the annual community education event taking place Tuesday, December 7, 2021 from 6:00 PM – 8:00 PM. This year, we will host the event virtually through a zoom webinar. The event is FREE and open to the community, but registration is required.
October 03, 2021
Long-acting pre-exposure prophylaxis (PrEP) is not only a long sought-after measure of HIV control in the infectious disease community—it’s a now tangible opportunity that would alter both diagnostics and care. In an interview with Contagion during IDWeek 2021, Raphael J. Landovitz, MD, MSc, of the UCLA Center for Clinical AIDS Research & Education, reviewed his own presentation on the current
September 09, 2021
The UCLA Center for Clinical AIDS Research & Education (CARE), UCLA Pacific AIDS Education Training Center (PAETC), UCLA AIDS Institute, and Center for HIV Identification, Prevention and Treatment Services (CHIPTS) proudly present the 18th Annual HIV CME Symposium "Tough Decisions Made Easier: Clinical Management of Treatment - Experienced Patients." This one-day virtual symposium is designed to
Where we came from. Where we are now. Where we need to go from here.
The purpose of this study is to evaluate the safety, tolerability, and efficacy of N-803, an IL-15 superagonist, with or without combination broadly neutralizing antibodies (bNAbs), to induce HIV-1 control during analytic treatment interruption (ATI). Interested in Volunteering? We are looking for HIV+ people who are taking antiretroviral treatment (ART) and whose viral load is undetectable. The goal is to find out if IL-15 is safe alone or when used in combination with another treatment called broadly neutralizing antibodies (bNAbs). Participants will receive 8 doses of IL-15 given every 3 weeks. Half of the participants will be randomly assigned to also receive the bNAbs with it. After completing these treatments, participants will temporarily stop taking their HIV medicine (ART) and will be evaluated to see how well this treatment controls their viral load. Basic Eligibility Criteria: Age: 18-65 years old Status: HIV Positive Continuous HIV treatment: at least 96 weeks Viral load: Undetectable at least 96 weeks Coinfection: No active hepatitis B or C infection CD4 count: More than 500 Principal Investigator: Kara Chew, MD, MS For more information, please contact the UCLA CARE Center: [email protected] 310-843-2015 If you would prefer to have a community outreach coordinator or research coordinator reach out to you, please leave your contact information below and someone will reach out to you shortly.
Antibodies that develop naturally against HIV recognize and attach to one part of the virus so that the body’s immune system can try to attack it. Antibodies are usually made by a person’s own immune system, but they can also be manufactured as a drug. SAR441236 has been manufactured to attach to three parts of the HIV virus at the same time, and to neutralize (or block) the ability of the virus to infect more cells. A5377 is the first study of SAR441236 in humans. This study will enroll two groups of people with HIV: Arm A—people who are on an anti-HIV regimen with an undetectable HIV viral load will receive either SAR441236 or placebo in four increasing dosing groups; and Arm B—people who have never received anti-HIV medications will receive SAR441236 in four increasing dosing groups. Interested in Volunteering? This UCLA research study is for people living with HIV who are not currently on ART. You may qualify if you: Are 18 years of age or older Are HIV+ Have a CD4+ cell count of at least 350 Are not currently taking antiretrovirals (ART) Are willing to start ART after 28 days on the study Have no Hepatitis B or C infection Principal Investigator: Raphael Landovitz, MD, MSc For more information, contact the UCLA CARE Center at: [email protected] 310-557-9062 If you would prefer to have a community outreach coordinator or research coordinator reach out to you, please leave your contact information below and someone will reach out to you shortly.
Having trouble taking your HIV medication every day? Might MONTHLY injections be right for you? This study is for people living with HIV to determine if LONG-ACTING, MONTHLY INJECTABLE medications will be more successful at keeping the viral load undetectable than the "standard" daily oral medications for people who have difficulty taking pills every day for HIV. Eligibility You may be eligible to participate in this study if you are: 18 years of age or older HIV + and have a DETECTABLE viral load Have trouble taking HIV medication regularly The study will last between 6 months and 3 ½ years depending on successful completion of each milestone in the study Principal Investigator: Raphael Landovitz, MD, MSc For more information, contact the UCLA CARE Center at: [email protected] 310-557-9062 There are limitations to the confidentiality of email communications. Do not include any sensitive health information if you choose to contact the study team via email. If you would prefer to have a community outreach coordinator or research coordinator reach out to you, please leave your contact information below and someone will reach out to you shortly.